|
カワムラ ヒデマサ
KAWAMURA Hidemasa
河村 英将 所属 埼玉医科大学 医学部 総合医療センター 放射線科(画像診断・核医学科、放射線腫瘍科) 職種 教授 |
|
| 論文種別 | 学術雑誌(原著) |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | PHASE I STUDY OF ORAL S-1 PLUS CISPLATIN WITH CONCURRENT RADIOTHERAPY FOR LOCALLY ADVANCED NON-SMALL-CELL LUNG CANCER |
| 掲載誌名 | 正式名：INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS ISSNコード：0360-3016 |
| 出版社 | ELSEVIER SCIENCE INC |
| 巻・号・頁 | 75(1),109-114頁 |
| 著者・共著者 | Kyoichi Kaira,Noriaki Sunaga,Noriko Yanagitani,Tadayoshi Kawata,Mitsuyoshi Utsugi,Kimihiro Shimizu,Takeshi Ebara,Hidemasa Kawamura,Tetsuo Nonaka,Hitoshi Ishikawa,Hideyuki Sakurai,Tatsuo Suga,Kenichiro Hara,Takeshi Hisada,Tamotsu Ishizuka,Takashi Nakano,Masatomo Mori |
| 発行年月 | 2009/09 |
| 概要 | Purpose: To determine the maximum tolerated dose (MTD) and recommended dose (RD) of S-1 in combination with cisplatin and thoracic radiotherapy in patients with unresectable Stage III non-small-cell lung cancer (NSCLC). Methods and Materials: S-1 was administered orally twice daily for 14 days and cisplatin on Days I and 8 of each cycle; this was repeated every 3 weeks. Doses of each drug were planned as follows: level 0, 50/40; level 1, 60/40; level 2, 70/40; level 3, 80/40 (S-1 [mg/m(-2) /day(-1)]/cisplatin [mg/m(-2)/day(-1)]). Thoracic radiation therapy was administered in 2 Gy fractions five times weekly to a total dose of 60 Gy. Results: Ten patients were enrolled in this study. All patients received 60 Gy of thoracic radiotherapy and 7 (70%) patients received four cycles of chemotherapy. At level 1, 2 of 3 patients experienced a delay exceeding 10 days in the cisplatin administration of Day 29. Grade 4 neutropenia and Grade 3 fever occurred in 1 and 1 patients, respectively. Nonhematologic toxicities were mild. None developed >= Grade 3 esophagitis or lung toxicity. At level 0, 2 of 7 patients developed dose-limiting toxicity. Thus, level 1 was considered the MTD and Level 0 was selected as the RD. Objective responses were seen in all patients. Conclusions: The RD is the level 0 dose, and this regimen is a feasible and well-tolerated regimen for the treatment of patients with Stage III NSCLC. (C) 2009 Elsevier Inc. |
| DOI | 10.1016/j.ijrobp.2008.06.1938 |
| PMID | 18929446 |